In vitro pharmacodynamic studies of IDG-16177, a Potent GPR40 agonist, for the Treatment of Type 2 Diabetes | Multispan, Inc

In vitro pharmacodynamic studies of IDG-16177, a Potent GPR40 agonist, for the Treatment of Type 2 Diabetes

In vitro pharmacodynamic studies of IDG-16177, a Potent GPR40 agonist, for the Treatment of Type 2 Diabetes

GPCR Target: GPR40

Authors: Jongmin Yoon, et al.

Journal: Diabetes 1 June 2021; 70 (Supplement_1): 122–LB.

Year Published: 2021